New Zealand Pharma has taken a new step towards bringing four commercial peptides over the next five years by building US commercial operations. New Zealand Pharma CEO Emmanuel Dulac said that they have already proven their capability to take multiple programs through the clinics and execute on them according to industry demands. To enjoy the benefits of these four peptides, New Zealand is preparing to take benefits from its own products through registration and commercialization.
Glepaglutide, which is a long-acting GLP-2 analog for treating short bowel syndrome, is in phase III studies in the US. Once it would be developed, it will be used for severe hypoglycemia type 1 diabetes management and congenital hyperinsulinism. For the first half of 2019, the country has reported sales of $3 million from an existing license agreement with Alexion. Details for investors are not yet published, but soon it would be available. These four USA peptides will stable the peptide market in New Zealand within the next five years.
Emmanuel Dulac said, “We have retained the full commercial rights for our late-stage programs, and assuming we get approval for glepaglutide and dasiglucagon in all indications, we are contemplating four launches in three years, starting in 2021. After a score assessment of market potential and partnerships, we concluded that building our own commercial presence in the US to market all of the products coming from our fully own programs is the best way for Zealand Pharma to maximize the value of our company and grow our assets.”
